"Exposure To Anti-TNF Therapy Linked To Reduced Parkinson’s Disease Risk"
Patients with inflammatory bowel disease (IBD) treated with anti-tumor necrosis factor alpha (anti-TNFα) therapy were found to be at significantly lower risk of developing Parkinson disease (PD) compared with those not exposed to anti-TNFα, according to a study published in JAMA Neurology. "Systemic inflammation is a major component of IBD, and it's also thought to contribute to the neuronal inflammation found in Parkinson's disease," explained Inga Peter, PhD, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai and lead investigator in the study. "We wanted to determine if anti-TNFα therapy, could mitigate a patient's risk in developing Parkinson's disease."
- Inga Peter, PhD, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai